JP Morgan Chase’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $211 | Buy |
+8
| New | +$230 | ﹤0.01% | 7246 |
|
|
2025
Q2 | – | Sell |
-3
| Closed | -$23 | – | 7255 |
|
|
2025
Q1 | $23 | Sell |
3
-2,100
| -100% | -$24.8K | ﹤0.01% | 7099 |
|
|
2024
Q4 | $47.8K | Buy |
2,103
+2,100
| +70,000% | +$25K | ﹤0.01% | 6031 |
|
|
2024
Q3 | $17 | Buy |
3
+2
| +200% | +$21 | ﹤0.01% | 7262 |
|
|
2024
Q2 | $9 | Hold |
1
| – | – | ﹤0.01% | 7216 |
|
|
2024
Q1 | $12 | Hold |
1
| – | – | ﹤0.01% | 7215 |
|
|
2023
Q4 | $14 | Hold |
1
| – | – | ﹤0.01% | 7394 |
|
|
2023
Q3 | $11 | Hold |
1
| – | – | ﹤0.01% | 7278 |
|
|
2023
Q2 | $18 | Hold |
1
| – | – | ﹤0.01% | 6792 |
|
|
2023
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 6851 |
|
|
2022
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 6670 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 6562 |
|
|
2022
Q2 | $0 | Sell |
1
-211
| -100% | -$6.7K | ﹤0.01% | 6580 |
|
|
2022
Q1 | $8K | Buy |
212
+34
| +19% | +$1.29K | ﹤0.01% | 6246 |
|
|
2021
Q4 | $9K | Hold |
178
| – | – | ﹤0.01% | 6351 |
|
|
2021
Q3 | $13K | Buy |
178
+5
| +3% | +$2.77K | ﹤0.01% | 6120 |
|
|
2021
Q2 | $146K | Buy |
+173
| New | +$156K | ﹤0.01% | 5389 |
|
|
2020
Q4 | – | Sell |
-39
| Closed | -$47K | – | 5716 |
|
|
2020
Q3 | $47K | Buy |
+39
| New | +$25.9K | ﹤0.01% | 4943 |
|
|
2020
Q2 | – | Sell |
-18
| Closed | -$8K | – | 5470 |
|
|
2020
Q1 | $8K | Sell |
18
-53
| -75% | -$20.7K | ﹤0.01% | 5071 |
|
|
2019
Q4 | $14K | Sell |
71
-221
| -76% | -$50.1K | ﹤0.01% | 5355 |
|
|
2019
Q3 | $73K | Sell |
292
-979
| -77% | -$1.49M | ﹤0.01% | 5011 |
|
|
2019
Q2 | $3.07M | Buy |
1,271
+62
| +5% | +$184K | ﹤0.01% | 3059 |
|
|
2019
Q1 | $4.93M | Buy |
1,209
+193
| +19% | +$746K | ﹤0.01% | 2596 |
|
|
2018
Q4 | $3.13M | Buy |
1,016
+33
| +3% | +$142K | ﹤0.01% | 2942 |
|
|
2018
Q3 | $5.75M | Sell |
983
-22
| -2% | -$83.8K | ﹤0.01% | 2630 |
|
|
2018
Q2 | $3.52M | Sell |
1,005
-513
| -34% | -$1.88M | ﹤0.01% | 2963 |
|
|
2018
Q1 | $6.75M | Sell |
1,518
-114
| -7% | -$528K | ﹤0.01% | 2327 |
|
|
2017
Q4 | $6.27M | Sell |
1,632
-49
| -3% | -$196K | ﹤0.01% | 2489 |
|
|
2017
Q3 | $7.89M | Buy |
1,681
+582
| +53% | +$2.59M | ﹤0.01% | 2184 |
|
|
2017
Q2 | $4.96M | Buy |
+1,099
| New | +$6.18M | ﹤0.01% | 2477 |
|
Other funds holding FBRX
FAM
O
AAA
MB
VCM
CCC
JP Morgan Chase's FBRX Position: Q1 2026 in Review
JP Morgan Chase opened a new position in Forte Biosciences (FBRX) in Q1 2026: 8 shares worth $211. The stake represents ﹤0.01% of the portfolio and ranks #7246 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in FBRX as recently as Q1 2025.
JP Morgan Chase first reported a position in FBRX in Q2 2017 and has held it in 30 quarters since. The position peaked at $7.89M in Q3 2017. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.
- JP Morgan Chase held 8 shares of Forte Biosciences worth $211 as of Q1 2026.
- Forte Biosciences was a new JP Morgan Chase position in Q1 2026.
- Forte Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7246 holding.
- JP Morgan Chase first reported a position in Forte Biosciences in Q2 2017 and has held it in 30 quarters since.
- JP Morgan Chase's Forte Biosciences position peaked at $7.89M in Q3 2017.
- 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.